Skip to the lineages
Regenerative Medicine

What Does It Mean When an FDA Investigational New Drug (IND) Application Is in Effect?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. What an IND is
  2. Sponsors, investigators and protocols
  3. The 30-day period
  4. Clinical holds
  5. How an IND differs from approval
  6. Oversight and risk in a study
  7. What to ask about a claimed IND

It means FDA has allowed a specific clinical investigation of an unapproved drug or biologic, or in some cases an authorized expanded-access treatment use, to proceed under its conditions, not that FDA has found the product safe or effective. For a research IND, according to FDA, the application goes into effect 30 days after FDA receives it, unless FDA places the studies on clinical hold, or sooner if FDA notifies the sponsor that the studies may begin. Once it is in effect, the product can be given to people in the described study, under the study’s rules. Approval to market a product for a condition is a separate, later decision.

What an IND is

An investigational new drug (IND) application is what a sponsor (a company or researcher) submits to FDA to study an unapproved drug or biological product in people. FDA’s IND application procedures overview lists the forms that accompany an application, including the cover form, the investigator’s statement, and a certification about registering applicable clinical trials and reporting their results on ClinicalTrials.gov. The application describes the product, the plan for the study and the investigators.

Sponsors, investigators and protocols

The sponsor is responsible for the application. Investigators are the clinicians who carry out the study. FDA states: “An investigator may not administer an investigational new drug to human subjects until the IND application goes into effect.” An IND covers the investigations it describes, not any use a clinic chooses.

There is one other IND route, for treatment rather than research. FDA describes expanded access, sometimes called compassionate use, as “a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.” FDA’s page on expanded access categories lists individual-patient, intermediate-size and widespread treatment use, each submitted either as a new IND or as a protocol under an existing IND, with timing rules that differ from the 30-day research rule below; in an emergency, treatment can begin on FDA’s authorization before the written submission arrives. It is a narrow exception for serious conditions, not a general route to routine joint injections.

The 30-day period

FDA explains that an IND application may go into effect:

  1. “30 days after FDA receives the application, unless FDA notifies the sponsor that the investigations described in the application are subject to a Clinical Hold”; or
  2. “on earlier notification by FDA that the clinical investigations in the IND may begin.”

FDA notifies the sponsor of the date it received the application through an acknowledgment letter. For a research IND, “in effect” therefore means the waiting period has passed without a hold, or FDA has allowed an earlier start. The research steps run as follows:

Milestone What it means
IND received FDA logs the date and sends an acknowledgment letter
30-day period FDA can place a clinical hold during this time
IND in effect The described studies may begin
Clinical studies Data on safety and effectiveness are gathered
Licensing decision A separate application and FDA review, later

Clinical holds

FDA can notify a sponsor that the described investigations are subject to a clinical hold, and in that case the IND does not go into effect at 30 days. FDA’s overview lists procedures related to clinical holds among the things investigators should know, so a sponsor’s claim that an IND is in effect is something to confirm rather than assume.

How an IND differs from approval

An IND allows a specific investigation, or an authorized expanded-access treatment use, under its conditions. Approval allows marketing. FDA’s consumer article Is It Really ‘FDA Approved’? explains that, with rare exceptions, new drugs and biological products “must be FDA approved before they are marketed,” and that approval means the company has shown the product “is safe and effective for the intended use.” For cell products, FDA’s patient and consumer information on regenerative medicine therapies says such products “require FDA oversight in a clinical trial” before approval, and that FDA “has repeatedly notified manufacturers, clinics, and health care practitioners of the need for Investigational New Drug applications (INDs) to legally administer these products.” How to check approval is covered in how you can tell whether a regenerative medicine product is FDA-approved.

Oversight and risk in a study

Being in a study under an IND brings protections, including informed consent. Federal rules at 21 CFR 50.25, available in the Legal Information Institute’s copy of 21 CFR 50.25, require that participants be told, among other things, that “the study involves research,” which procedures “are experimental,” “any reasonably foreseeable risks or discomforts,” and that “participation is voluntary.” Those requirements are covered in what should be included in informed consent for an experimental biologic injection. Research also carries risk: the product is being studied precisely because its safety and effectiveness are not yet established.

What to ask about a claimed IND

If a clinic says its product is given under an IND, ask:

  1. What is the IND number, and who is the sponsor?
  2. Can I see FDA’s communication acknowledging the IND? FDA’s 2019 Public Safety Notification on Exosome Products advises patients to ask the investigator for “the FDA-issued Investigational New Drug Application (IND) number and the chance to review the FDA communication acknowledging the IND.”
  3. Is the treatment I am being offered part of the study described in that IND, or an authorized expanded-access use, and what protocol and consent form apply?
  4. Is the study registered on ClinicalTrials.gov, and what does the record say? Registry records are covered in whether listing a study on ClinicalTrials.gov means a treatment is approved.
  5. Will I be charged, and for what?

An IND in effect means FDA has allowed a specific clinical investigation, or an authorized expanded-access treatment use, of an unapproved product to proceed under its conditions, but it is not marketing approval or a finding that the product is safe, effective or approved for any condition.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage I: Patient Safety, Scientific Literacy and FDA Verification

What readers added

Add a remark

Your email address will not be published. Required fields are marked *